ArticleJournal of experimental & clinical cancer research : CR2025
FGD3 mediates lytic cell death, enhancing efficacy and immunogenicity of chemotherapy agents in breast cancer.
Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundAlthough anticancer therapies inducing necrosis, necroptosis and pyroptosis trigger cell swelling, plasma membrane rupture (PMR) and release of damage-associated molecular patterns (DAMPs), potentially facilitating antitumor immunity, little was known of proteins and mechanisms controlling the life-death decision of whether swollen and stressed cancer cells enter PMR and undergo lytic cell death.
methodsWe conducted a genome-wide CRISPR screen with selection against a lytic cell death inducer, complemented by studies using breast cancer cells in 2D culture, patient-derived organoids and orthotopic mouse xenografts. The effect of FGD3 on immunogenicity was explored by immunoblotting, immunofluorescence staining and NK-cell mediated cytotoxicity assays. The correlation between the level of FGD3 expression and patient prognosis and response to chemotherapy was assessed by analysis of patient databases.
resultsWe identified FGD3 as a key mediator, coupling cell swelling to PMR and lytic cell death induced by emerging and current breast cancer therapies, including ErSO, aprepitant, doxorubicin and epirubicin. FGD3 coupled cell swelling to PMR across the spectrum of immunogenic lytic cell death pathways, including necrosis, necroptosis and pyroptosis. Mechanistically, FGD3 facilitated PMR by controlling actin reorganization via the Cdc42-ARP2/3 axis. Notably, elevated FGD3 increased release of DAMPs, strongly enhanced exposure of immunogenic cell surface calreticulin and increased sensitivity of cancer cells to NK cell-mediated lysis. Supporting clinical relevance, high FGD3 expression strongly correlated with improved relapse-free survival in breast cancer patients after chemotherapy and this correlation was stronger than was seen for NINJ1 and other proteins associated with lytic cell death.
conclusionFGD3 is a key mediator of chemotherapy-induced plasma membrane rupture and lytic cell death. It is also a useful biomarker for identifying breast cancer patients most likely to benefit from lytic cell death-inducing immunogenic anticancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.